What's Happening?
The AAV gene therapy market is projected to grow significantly, reaching USD 23.5 billion by 2034. This growth is driven by advancements in gene therapy, particularly in treating rare diseases, oncology, and inherited disorders. AAV vectors benefit from improved regulatory pathways and expanding manufacturing infrastructure. The market is supported by technological innovations, including advanced viral vector engineering and scalable bioprocessing systems. The neurological disorders segment accounts for the largest share, with AAV9 being the most widely used vector due to its ability to cross the blood-brain barrier.
Why It's Important?
The growth of the AAV gene therapy market is crucial for the development of treatments for rare and complex diseases. AAV vectors
offer a promising approach for delivering genetic therapies, particularly for neurological disorders where conventional treatments are limited. The expansion of manufacturing capabilities and regulatory support accelerates the development and commercialization of AAV-based therapies. This market growth reflects the increasing demand for personalized medicine and the potential for gene therapy to transform healthcare by providing targeted and effective treatments.
